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Rituximab modulates the
expression of IL-22 in the salivary
glands of patients with primary
Sjogren’s syndrome
We have recently demonstrated that interleukin (IL)-22, mainly
produced by T-helper 17 effector cells, natural killer (NK)p44
+NK cells and epithelial cells, may be potentially involved in
the pathogenesis of primary Sjogren’s syndrome (pSS).1 The
IL-22/IL-22R pathway is known to play a role in the emergence
of T and B-cell lymphoma2 3 and pSS is considered a risk factor
for the development of lymphoma.4
Rituximab, which has historically been used for the treat-
ment of B-cell lymphoma,5 has also been considered to be
effective in the therapy of pSS.6
Ten consecutive patients with pSS (eight women and two
men, with a mean duration of disease of 48±18 months), diag-
nosed according to the American–European Consensus Group
criteria for pSS,7 who were treated with two courses of intra-
venous infusions of 1000 mg rituximab (Roche, Woerden, The
Netherlands) at days 1 and 15, at baseline and then after
6 months, were considered for this study. After 48 weeks the
patients again underwent salivary gland biopsy. The demo-
graphic, clinical and histological characteristics of the patients
are shown in table 1. Ethics approval was granted and written
consent was obtained from all patients. Evaluation of the clin-
ical efﬁcacy of rituximab treatment was done by measuring the
improvement between day 1 and week 48 in the values of saliv-
ary and lacrimal gland function. Unstimulated whole, parotid
and submandibular/sublingual saliva samples were collected, as
described by Meijer et al.8 Lacrimal gland function was evalu-
ated by performing the Schirmer ’s test. Immunohistochemistry
for IL-22 was performed, as previously described, on
parafﬁn-embedded salivary gland biopsies by using a rabbit
anti-human IL-22 antibody.1 The number of IL-22+ cells was
determined by counting, in a blinded fashion before and after
rituximab treatment, IL-22 immunoreactive cells on photomi-
crographs obtained from three random high-power microscopic
ﬁelds (400× magniﬁcation). Intense IL-22 staining was
observed among inﬁltrating mononuclear cells, epithelial and
myoepithelial cells. Rituximab treatment signiﬁcantly reduced
the number of IL-22+ cells inﬁltrating the salivary glands of
pSS patients (table 1 and ﬁgure 1A,B). The expression of IL-22
by epithelial cells was also reduced in those patients displaying
a lower focus score (table 1 and ﬁgure 1C,D). Interestingly,
rituximab treatment speciﬁcally abolished the production of
IL-22 by myoepithelial cells (ﬁgure 1E,F). The whole saliva
ﬂow rate and the lacrimal gland function showed a signiﬁcant
improvement after rituximab therapy from baseline to week 48
(whole saliva ﬂow, ml/min (mean±SD) 0.24±0.12 at baseline
and 0.45±0.15 at week 48, p=0.0003; Schirmer ’s test, mm/
5 min (mean±SD) 4.7±1.5 at baseline and 8.7±2.11 at
48 weeks, p=0.00011)). A trend (although not statistically sig-
niﬁcant) towards a major improvement in salivary and lacrimal
glands was detected in those patients with a major reduction
in the numbers of IL-22+ cells after rituximab therapy.
Although we cannot exclude the possibility that the reduc-
tion in IL-22 may be due to the natural history of the disease,
these preliminary results suggest that rituximab therapy may
modify the immunological micro-environment of inﬂamed sal-
ivary glands of pSS patients reducing the local expression of
IL-22, providing an additional immunological explanation for
rituximab efﬁcacy in pSS. The immunological effects of rituxi-
mab therapy beyond B-cell depletion have recently been
demonstrated. In this regard, a reduction in the T-helper 17
response in the synovial tissues of patients with rheumatoid
arthritis has been observed after rituximab therapy.9 Even if a
possible explanation for these immunological changes could
reside in the reduction of the presentation of antigen from B to
T cells, the exact mechanisms by which rituximab therapy
modiﬁes the IL-22 response in pSS remain to be elucidated. As
with the role of IL-22/IL-22RA1 in the pathogenesis of B and
T-cell lymphoma,2 3 the rituximab-dependent reduction of
IL-22 expression may also be of relevance in reducing the risk
of the evolution of pSS towards lymphoma.
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Table 1 Clinical and histological characteristics of the pSS patients
Age/
sex
Disease
duration
(months)
ENA
anti-RoSSA/
LaSSB
Focus score pre/
post-rituximab
N of IL-22+
infiltrating cells pre/
post-rituximab
N of IL-22+
myoepithelial cells
pre/post-rituximab
Saliva flow rate ml/min
pre/post-rituximab
(mean)
Schirmer’s test,
mm/5 min
(mean)
Patient 1 38/F 44 +/+ 3/2 41/22 30/18 0.2/0.4 5/10
Patient 2 44/F 22 +/− 4/4 54/24 22/16 0.3/0.5 6/12
Patient 3 52/F 36 +/+ 4/3 44/33 18/13 0.13/0.33 5/8
Patient 4 43/F 28 +/+ 3/3 41/18 21/9 0.18/0.5 4/9
Patient 5 45/F 48 −/− 2/2 34/19 18/7 0,25/0.6 7/8
Patient 6 39/F 96 −/− 3/3 28/21 24/11 0,2/0.3 6/6
Patient 7 54/F 60 +/+ 2/2 23/16 13/6 0.16/0.33 3/7
Patient 8 42/F 96 +/+ 3/2 22/11 18/9 0.13/0.45 2/9
Patient 9 72/M 60 −/− 4/3 18/14 23/10 0.4/0.6 4/12
Patient
10
52/M 48 +/− 3/3 28/21 26/14 0.5/0.88 5/9
pSS, primary Sjogren’s syndrome; ENA, Extractable Nuclear Antigen.
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Figure 1 IL-22 expression in salivary glands of patients with primary Sjogren’s syndrome (pSS) is modiﬁed by rituximab (RTX) treatment.
Representative immunostaining for IL-22 in the pSS patient number 3 before and after therapy with rituximab. Positive inﬁltrating mononuclear cells
observed before therapy (A) were signiﬁcantly reduced after rituximab treatment (B) The intense immunostaining observed at baseline in
myoepithelial cells (D) was also drastically reduced in rituximab-treated patients (arrows) (E). (C–F) immunohistochemical quantiﬁcation of IL-22+
inﬁltrating cells (C) and myoepithelial cells (F) in salivary gland biopsies from pSS before and after rituximab therapy. Results are expressed as the
number of positive cells per ﬁeld. Data are shown as box plots. Each box represents the 25th to 75th percentiles. Lines inside the boxes represent
the median. Lines outside the boxes represent the 10th and 90th percentiles. (A, B) original magniﬁcation × 25; (D, E) original magniﬁcation × 63.
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